Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia.
Pfizer CT.gov Call Center
United States: Food and Drug Administration
|Pfizer Investigational Site||Blendora, California 91740|
|Pfizer Investigational Site||Houston, Texas 77030|
|Pfizer Investigational Site||Shreveport, Louisiana 71103|